Focus On: T2D and CKD | GPnotebook Resources

This promotional website has been developed, organised and funded by Boehringer Ingelheim.

Prescribing information for the United Kingdom and Republic of Ireland.
Adverse event reporting information can be found at the bottom of the page.

Focus on:
Type 2 diabetes (T2D) and
chronic kidney disease (CKD)

DID YOU KNOW?

Approximately 45,000 premature deaths in UK every year are due to CKD¹

Experts are urging for more to be done to:

Help patients recognise the signs of CKD and engage with CKD testing²
Support HCPs with the early detection of CKD and identifying opportunities for intervention³

UACR testing is an early indicator of kidney damage;⁴ however, the most recent National Diabetes Audit shows that almost 40% of people with T2D in England did not have a UACR test in the past year.⁵ One reason why UACR testing is low is because patients do not provide urine samples when requested.⁶ There is therefore an urgent need to improve rates of UACR testing in people at risk of, or living with CKD.⁷

Download a leaflet for your patients below, which outlines the purpose of UACR testing and the importance of returning urine samples. This leaflet was made in collaboration with Sanjay Mistry, an expert through experience, using patient-friendly language.

Click here to download patient leaflet

What has diabetes got to do with my kidneys?

Print and share this leaflet with your patients, which explains CKD in simple language, and the importance of UACR testing in the early detection of CKD

CLICK HERE TO ACCESS THE MODULE

Renal considerations in T2D prescribing

Developed in collaboration with Dr Lavan Baskaran

Learning Objectives

Understand the importance of renal function monitoring in T2D
Identify key testing parameters and frequency
Develop effective patient communication strategies
Explore treatment options based on kidney function
Recognise appropriate patient selection for different therapeutic options

Chronic kidney disease in adult type 2 diabetes: Practical advice for screening, management and referral

In this short video summary, Dr Janaka Karalliedde explores the relationship between CKD, T2D and cardiovascular disease. Discover more about the importance of the early identification of CKD and the multifactorial approaches and guideline-led treatment strategies available for managing your adult patients with CKD.

CLICK HERE TO VIEW SUMMARY VIDEO

Click here to view webinar resources

Sarah Jarvis
Webinar Series Chair

Watch the most recent webinar

Initiated and funded by
Boehringer Ingelheim

PC-GB-110175 V2 | December 2024

CKD: chronic kidney disease; HCP: healthcare professional; T2D: type 2 diabetes; UACR: urine albumin-to-creatinine ratio

References:

Kidney Care UK (2024). Key facts about kidneys. Available at: https://kidneycareuk.org/kidney-disease-information/about-kidney-health/facts-about-kidneys/ (accessed March 2025)
Kidney Research UK (2018). Kidney Research UK and Diabetes UK joint statement. Available at: https://www.kidneyresearchuk.org/research/partnerships-collaboration/kidney-research-uk-and-diabetes-uk-joint-statement/ (accessed March 2025)
Kidney Research UK (2024). Chronic kidney disease and prevention: Harnessing the potential of early intervention and disease management. Available at: https://www.kidneyresearchuk.org/wp-content/uploads/2023/03/Kidney-Research-report-on-prevention-and-early-detection.pdf (accessed March 2025)
Christofides EA and Desai N. J Prim Care Community Health 2021;12:21501327211003683
NHS England (2023). National Diabetes Audit 2021-22, Report 1: Care Processes and Treatment Targets, Overview. Available at: https://digital.nhs.uk/data-andinformation/publications/statistical/national-diabetes-audit/core-1-2021-22-overview#chapter-index (accessed March 2025)
Kidney Research UK (2020). Type 2 diabetics are missing out on an annual kidney test. Available at: https://www.kidneyresearchuk.org/2020/02/20/type-2-diabeticsare-missing-out-on-an-annual-kidney-test/ (accessed March 2025)
UK Kidney Association (2024). Measurement of kidney function. Available at: https://www.ukkidney.org/health-professionals/information-resources/uk-eckd-guide#measurement-of-kidney-function (accessed March 2025)

Prescribing information for the United Kingdom and Republic of Ireland.

Trajenta is indicated in adults with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control as:
• monotherapy when metformin is inappropriate due to intolerance, or contraindicated due to renal impairment
• in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control

This promotional website has been developed, organised and funded by Boehringer Ingelheim. Editorial support for this website has been provided by OmniaMed Communications.

Adverse events should be reported. Reporting forms and information can be found at https://www.mhra.gov.uk/yellowcard (UK) or https://www.hpra.ie/homepage/about-us/report-an-issue (IRE). Adverse events should also be reported to Boehringer Ingelheim Drug Safety on 0800 328 1627 (freephone) (UK) or 01 2913960 (IRE), Fax: +44 1344 742661, or by e-mail: [email protected].

PC-GB-110300 V2 | March 2025

PC-GB-110301 V2 | March 2025